Cosmas D. Arnold

Abstract Chimeric antigen receptor (CAR) T cell therapy has shown remarkable success in treating blood cancers, but CAR T cell dysfunction remains a common cause of treatment failure1. Here we present CELLFIE, a CRISPR screening platform for enhancing CAR T cells across multiple clinical objectives.

Abstract Transcriptional cofactors (COFs) communicate regulatory cues from enhancers to promoters and are central effectors of transcription activation and gene expression1. Although some COFs have been shown to prefer certain promoter types2,3,4,5 over others (for example, see refs 6,7), the extent to which different COFs display intrinsic specificities for distinct promoters is unclear.

The Regulatory Genome Multicellular organisms contain a variety of cell types that are morphologically and functionally distinct even though they typically contain the same genomic DNA. Differences stem from differential gene expression. Gene regulatory genomic regions (enhancers) are well studied, yet despite major efforts, such as Encode and modEncode, the number of enhancers in animal genomes and their genomic positions, cell-type specificity, and strengths are largely unknown. Arnold et al. (p.